Alexander M. Lesokhin
Memorial Sloan Kettering Cancer Center
282 Papers
526 Citations
Alexander M. Lesokhin is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Multiple myeloma. The author has an hindex of 33, co-authored 138 publications. Previous affiliations of Alexander M. Lesokhin include Cornell University & Bristol-Myers Squibb.
Chat about Author
Papers
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
Sarina Anne Piha-Paul,Ravit Geva,Tira Jing Ying Tan,Darren W.T. Lim,Cinta Hierro,Toshikiko Doi,Osama E. Rahma,Alexander M. Lesokhin,Alexander M. Lesokhin,Jason J. Luke,Jason J. Luke,Javier Otero,Lisa Nardi,Angad P Singh,A. Xyrafas,Xinhui Chen,Jennifer Marie Mataraza,Philippe L. Bedard +17 more
TL;DR: In this paper, the safety and tolerability of GWN323 were investigated in patients with advanced/metastatic solid tumors with Eastern Cooperative Oncology Group performance status of ≤ 2.
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma.
B. O. Adegbite,C. Tan,Tala Shekarkhand,Ross Firestone,Eric M Jurgens,Kevin C Miller,Alexander M. Lesokhin,G. Shah,Neha Korde,Sridevi Rajeeve,Heather J Landau,Michael Scordo,Hani Hassoun,Kylee H Maclachlan,U. Shah,M. Hultcrantz,Issam Hamadeh,Andriy Derkach,D. M. Nemirovsky,S. Giralt,Sham Mailankody,Saad Z Usmani,Hamza Hashmi +22 more
TL;DR: Frail patients with relapsed/refractory multiple myeloma receiving BCMA-directed bispecific antibodies (BsAbs) experience safe and effective outcomes, with advanced age, poor performance status, and comorbidities not predicting inferior outcomes.
P-038 Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
Noriko Nishimura,Jessica R. Flynn,Bruno Costa,Sean M. Devlin,Tasmin Farzana,Karthik Nath,David Chung,Heather Landau,Oscar B Lahoud,Michael Scordo,Gunjan L. Shah,Hani Hassoun,Kylee H Maclachlan,Malin Hultcrantz,Neha Korde,Alexander M. Lesokhin,Urvi A Shah,C. Tan,Sergio Giralt,Saad Usmani,Sham Mailankody +20 more
TL;DR: This study evaluates the impact of absolute lymphocyte count on CAR-T therapy outcomes in relapsed refractory multiple myeloma, demonstrating durable responses and efficacy across all tested dose levels, with a 89% overall response rate and 10^-5 MRD-negative CRs at 3 months.
Abstract CT097: A first-in-human phase I dose escalation study of the OX40 agonist MOXR0916 in patients with refractory solid tumors
Aaron R. Hansen,Jeffrey R. Infante,Grant A. McArthur,Michael S. Gordon,Alexander M. Lesokhin,Ann-Lee Stayner,Todd M. Bauer,Shahneen Sandhu,Frank Tsai,Alexandra Snyder,Deepa S. Subramaniam,Jeong Kim,Eric Stefanich,Chi-Chung Li,Jane Ruppel,Maria Anderson,Houston Gilbert,Bruce McCall,Mahrukh Huseni,Ina Rhee,Michael J. Pishvaian +20 more
TL;DR: Tumor PD modulation and evidence of prolonged stable disease support the ongoing expansion phase to evaluate anti-tumor activity in select indications and Phase Ib trial in combination with atezolizumab (anti-PD-L1).
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma
C. Tan,Kylee H Maclachlan,D. M. Nemirovsky,Andriy Derkach,Malin Hultcrantz,Hani Hassoun,Sham Mailankody,Urvi A Shah,Sridevi Rajeeve,Dhwani Patel,Tala Shekarkhand,Colin Rueda,Oscar B Lahoud,Gunjan L. Shah,Michael Scordo,David Chung,Heather Landau,Sergio A. Giralt,Alexander M. Lesokhin,Saad Usmani,Neha Korde +20 more
TL;DR: Early outcomes associated with DVRd and DKRd induction in the management of patients with NDMM are examined, resulting in deep responses and high minimal residual disease (MRD) negativity rates.